BioNTech (NASDAQ:BNTX) Sets New 1-Year Low at $81.72

BioNTech SE (NASDAQ:BNTX) shares hit a new 52-week low during mid-day trading on Thursday . The company traded as low as $81.72 and last traded at $82.41, with a volume of 88825 shares traded. The stock had previously closed at $82.52.

Analyst Ratings Changes

A number of brokerages have issued reports on BNTX. The Goldman Sachs Group lowered their target price on BioNTech from $113.00 to $100.00 and set a “neutral” rating for the company in a report on Wednesday, February 28th. Evercore ISI started coverage on BioNTech in a research note on Tuesday, May 14th. They issued an “inline” rating and a $100.00 price target for the company. TD Cowen increased their price target on BioNTech from $95.00 to $98.00 and gave the company a “hold” rating in a research note on Tuesday, May 7th. UBS Group decreased their price target on BioNTech from $110.00 to $101.00 and set a “neutral” rating for the company in a research note on Wednesday, March 27th. Finally, BMO Capital Markets decreased their price target on BioNTech from $123.00 to $122.00 and set an “outperform” rating for the company in a research note on Tuesday, May 7th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $111.70.

BioNTech Trading Down 1.5 %

The company has a current ratio of 11.38, a quick ratio of 11.16 and a debt-to-equity ratio of 0.01. The firm has a 50-day moving average of $92.46 and a 200 day moving average of $94.94. The company has a market cap of $19.33 billion, a P/E ratio of 165.04 and a beta of 0.27.

BioNTech (NASDAQ:BNTX) last announced its earnings results on Monday, May 6th. The company reported ($1.42) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.60). BioNTech had a net margin of 4.01% and a return on equity of 0.55%. The business had revenue of $203.69 million for the quarter, compared to the consensus estimate of $589.96 million. On average, analysts predict that BioNTech SE will post -2 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BioNTech

Several institutional investors and hedge funds have recently made changes to their positions in BNTX. GAMMA Investing LLC boosted its holdings in BioNTech by 121.0% in the first quarter. GAMMA Investing LLC now owns 274 shares of the company’s stock worth $25,000 after acquiring an additional 150 shares in the last quarter. CWM LLC lifted its holdings in shares of BioNTech by 657.6% in the fourth quarter. CWM LLC now owns 250 shares of the company’s stock valued at $26,000 after purchasing an additional 217 shares in the last quarter. Frazier Financial Advisors LLC bought a new position in shares of BioNTech in the fourth quarter valued at approximately $30,000. Covestor Ltd bought a new position in shares of BioNTech in the third quarter valued at approximately $32,000. Finally, First Horizon Advisors Inc. bought a new position in shares of BioNTech in the fourth quarter valued at approximately $38,000. Institutional investors own 15.52% of the company’s stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.